NRX Pharmaceuticals Files Reg FD Disclosure — Investor Presentation Used Sept 8, 2026

What Happened

• NRX Pharmaceuticals, Inc. filed a Current Report on Form 8‑K on September 14, 2026 (Item 7.01) disclosing that company representatives used an investor presentation on September 8, 2026 in presentations and meetings with investors and other persons. The investor presentation is furnished as Exhibit 99.1 to the 8‑K. The company stated it may continue to use the presentation, in whole or in part, and possibly with modifications, in future investor/analyst presentations.

Key Details

• Filing: Form 8‑K filed September 14, 2026 (Item 7.01 — Regulation FD Disclosure).
• Presentation used: Investor presentation dated September 8, 2026 — furnished as Exhibit 99.1.
• Ongoing use: Company may continue to use the presentation, in whole or in part, and may modify it for future presentations.
• Technical exhibit: Cover page Inline XBRL tags provided as Exhibit 104.

Why It Matters

• This is a Regulation FD disclosure: NRX is formally notifying the market that it used a specific investor presentation in communications with investors.
• The filing itself does not report earnings, management changes, or a transaction; it documents disclosure of investor materials.
• Retail investors should review Exhibit 99.1 (the investor presentation) for any material information or updates about the company’s business or plans and watch for related filings that might contain financial results or substantive corporate developments.